Tag: Dr Daniel Adelman

Palforzia

New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued...

After 2 Years of Daily Treatment, More Than 80% of Patients Were Successfully Desensitized to 2000 mg Peanut Protein or Equivalent of About 14 Peanut Kernels.
AR101

Phase 3 Trial Data Demonstrates Consistent Safety and Efficacy of AR101...

“Results of the European ARTEMIS trial provide further clinical validation of the safety and efficacy of AR101 for children and adolescents with peanut allergy.”
AR101

Aimmune Therapeutics Presents New AR101 Data Including Demonstrated Reduction in Accidental...

AR101-Treated Patients Who Completed PALISADE Had 95% Increased Probability of Tolerating Any Dose of Peanut Protein in Exit Challenge Compared to Placebo.